Research activity information

• Jan. 2026 神戸腎臓ネットワーク, Kobe Nephrology Award, Renoprotective effects of SGLT2 inhibitors in patients with Fabry disease. Mol Genet Metab Rep. 2025;45:101271.


• Jul. 2025 Japan Fabry Disease Forum Research Grant (2025), 兵庫県全域における血液透析患者のファブリー病スクリーニングに関する観察研究

• The calcimimetic etelcalcetide attenuates pressure overload-induced cardiac hypertrophy in rats with and without chronic kidney disease.

  Hidehisa Okamoto, Shunsuke Goto, Yuma Nose, Hayaki Okamoto, Hideki Fujii

  INTRODUCTION: Calcimimetics such as etelcalcetide (ET) are used to manage secondary hyperparathyroidism patients with chronic kidney disease (CKD) on dialysis. While their cardiovascular benefits-including left ventricular hypertrophy (LVH) suppression-are recognized, the underlying mechanisms remain unclear. This study investigated how ET suppresses LVH using rat models. METHODS: LVH was induced via transverse aortic coarctation, and CKD by 5/6 nephrectomy. Rats were assigned to the sham, CKD, LVH, or CKD/LVH groups, with each pathological group further divided into vehicle- or ET-treated subgroups. After eight weeks of treatment, echocardiography, histological, biochemical, and molecular analyses were conducted. RESULTS: ET reduced serum parathyroid hormone and fibroblast growth factor 23 (FGF23) levels in the CKD and CKD/LVH groups but not in the LVH group, where these levels were not increased. ET did not affect serum calcium, phosphorus, or vitamin D levels in the LVH and CKD/LVH groups. Nonetheless, ET suppressed cardiac hypertrophy and cardiomyocyte enlargement in the LVH and CKD/LVH groups despite no changes in systemic mineral metabolism parameters. Mechanistically, ET attenuated cardiac hypertrophy, serum aldosterone levels, and cardiac renin-angiotensin-aldosterone system (RAAS) components in the LVH and CKD/LVH groups. Cardiac FGF23 expression, elevated in the LVH and CKD/LVH groups, was also decreased by ET. The calcineurin/nuclear factor of the activated T-cell signaling pathway was unaffected. CONCLUSION: ET effectively suppressed LVH in the LVH and CKD/LVH groups. These findings suggest that ET's cardioprotective effects are mediated via the modulation of the RAAS and cardiac FGF23 expression rather than solely through the correction of CKD-mineral bone disorder abnormalities.

  Jan. 2026, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 196, 119054 - 119054, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Relative versus Absolute Globotriaosylsphingosine Changes and Kidney Outcomes in Fabry Disease

  Toshiyuki Hirai, Shunsuke Goto, Hayaki Okamoto, Momoko Tabuchi, Mika Fujita, Hideki Fujii

  2026


• Renoprotective effects of SGLT2 inhibitors in patients with Fabry disease.

  Hayaki Okamoto, Shunsuke Goto, Mika Fujita, Hideki Fujii

  BACKGROUND: Fabry disease (FD) is a rare X-linked lysosomal storage disorder characterized by globotriaosylceramide (Gb3) accumulation, resulting in kidney and cardiac dysfunction. Although enzyme replacement therapy (ERT) and chaperone therapy are the standard therapies, progression of renal decline persists. Sodium-glucose co-transporter 2 (SGLT2) inhibitors exert renoprotective effects in chronic kidney disease (CKD), but their efficacy in FD remains unknown. METHODS: We retrospectively analyzed data of 10 patients with FD treated with SGLT2 inhibitors and compared their renal outcomes to 18 patients with CKD without FD. The estimated glomerular filtration rate (eGFR) slope, urinary albumin-to-creatinine ratio (UACR), and plasma brain natriuretic peptide (BNP) levels were assessed 1 year before and after initiating SGLT2 inhibitor therapy. Linear mixed-effects models were employed for statistical analysis. RESULTS: In patients with FD, the annual eGFR decline significantly improved from -4.38 mL/min/1.73 m2/year (IQR: -10.57 to 0.59) before treatment to 1.25 (IQR: -4.16 to 9.74) after treatment (p < 0.05). This improvement remained significant after adjusting for confounding factors. In contrast, the annual eGFR decline in patients with CKD without FD also tended to improve, albeit without significance. Notably, the initial eGFR decline usually seen with SGLT2 inhibitors in CKD was not observed in the FD cohort. UACR and plasma BNP levels remained unchanged after SGLT2 inhibitor therapy. CONCLUSIONS: SGLT2 inhibitors substantially attenuated the decline in eGFR in patients with FD. These findings support their potential as a renoprotective adjunct in the management of FD.

  Dec. 2025, Molecular genetics and metabolism reports, 45, 101271 - 101271, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• Co-localization of IgG with nephrin in immune-mediated idiopathic nephrotic syndrome.

  Yuta Ichikawa, Nana Sakakibara, Shuhei Aoyama, Yuka Kimura, Yuta Inoki, Yu Tanaka, Chika Ueda, Hideaki Kitakado, China Nagano, Tomohiko Yamamura, Shingo Ishimori, Yuko Shima, Hayaki Okamoto, Hideki Fujii, Hironobu Maruyama, Kazumoto Iijima, Kandai Nozu, Tomoko Horinouchi

  BACKGROUND: Increased serum anti-nephrin antibody titers and co-localization of nephrin and IgG in kidney tissues have been reported in minimal change disease (MCD) and post-transplant recurrent focal segmental glomerulosclerosis (FSGS). These results indicate an association of anti-nephrin antibodies with nephrotic syndrome (NS); however, the exact relationship remains unclear. Herein, we evaluated nephrin/IgG co-localization in the glomeruli of patients with various kidney diseases, including monogenic NS, to clarify the association between idiopathic nephrotic syndrome (INS) and anti-nephrin antibodies. METHODS: IgG and nephrin co-localization was investigated in 52 kidney tissue biopsy samples, comprising INS in the active phase (n = 26; MCD, n = 19; FSGS, n = 7) and remission (n = 6), monogenic NS (n = 3), and other kidney diseases (n = 17). Double-immunofluorescence staining for nephrin/IgG was performed in unfixed frozen sections for 2 h at room temperature with Alexa Fluor-labeled nephrin/IgG cocktail antibodies. Nephrin/IgG co-localization was assessed using optical sectioning under a fluorescence microscope. RESULTS: Nephrin/IgG co-localization was observed in 81% (21/26, children: 15/17, adults: 6/9) of active INS cases, 84% (16/19) of MCD cases, and 71% (5/7) of FSGS cases. No co-localization was observed in NS with monogenic variants or other kidney diseases. CONCLUSION: Nephrin/IgG co-localization in the kidney tissue is finding observed in active INS, strongly indicating an association between anti-nephrin antibodies and INS onset. The nephrin/IgG cocktail antibody is a rapid and effective approach for investigating INS pathogenesis that facilitates the differential diagnosis of immune-mediated NS from other kidney diseases, including monogenic NS.

  Aug. 2025, Clinical and experimental nephrology, 29(12) (12), 1821 - 1828, English, Domestic magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 混合効果モデルを用いたFabry病患者におけるSGLT2阻害薬のeGFR slopeへの影響に関する検討

  岡本 隼樹, 後藤 俊介, 藤田 美佳, 藤井 秀毅

  (一社)日本腎臓学会, Jun. 2025, 日本腎臓学会誌, 67(4) (4), 571 - 571, Japanese


• 抗ネフリン抗体の関与が疑われた巣状分節性糸球体硬化症の腎移植後再発の一例

  黒野 博義, 河野 圭志, 市川 裕太, 兵頭 俊紀, 岡本 隼樹, 坂本 和雄, 後藤 俊介, 兵頭 洋二, 野津 寛大, 藤井 秀毅

  (一社)日本移植学会, Nov. 2024, 移植, 59(2) (2), 208 - 209, Japanese


• 臨床研究フロンティア ファブリー病患者における骨密度についての知見とスクリーニングへの取り組み

  能瀬 勇馬, 後藤 俊介, 後藤 公彦, 岡本 隼樹, 藤井 秀毅

  (一社)日本腎臓学会, Sep. 2024, 日本腎臓学会誌, 66(6-W) (6-W), 1051 - 1051, Japanese


• カルシウム感知受容体(CaSR)作動薬による心肥大抑制とレニン-アンジオテンシン-アルドステロン系(RAAS)の変化

  岡本 英久, 能瀬 勇馬, 岡本 隼樹, 渡邉 健太郎, 坂本 和雄, 河野 圭志, 後藤 俊介, 藤井 秀毅

  (一社)日本腎臓学会, Jun. 2024, 日本腎臓学会誌, 66(4) (4), 644 - 644, Japanese


• Fabry病における酵素補充療法前後の血中Lyso-Gb3の変化率に関する検討

  平井 俊行, 後藤 俊介, 岡本 隼樹, 坂本 和雄, 河野 圭志, 藤井 秀毅

  (一社)日本腎臓学会, Jun. 2024, 日本腎臓学会誌, 66(4) (4), 675 - 675, Japanese


• Fabry病におけるSGLT2阻害薬による心・腎保護効果の検討

  藤田 美佳, 岡本 隼樹, 平井 俊行, 後藤 俊介, 藤井 秀毅

  (一社)日本腎臓学会, Jun. 2024, 日本腎臓学会誌, 66(4) (4), 675 - 675, Japanese


• Investigation of bone mineral density and the changes by enzyme replacement therapy in patients with Fabry disease.

  Yuma Nose, Hideki Fujii, Shunsuke Goto, Keiji Kono, Hayaki Okamoto, Kentaro Watanabe, Shinichi Nishi

  BACKGROUND: Fabry disease (FD) is an inherited disorder that causes organ dysfunction. However, only a few studies have reported on bone mineral density (BMD) in FD patients, and the relationship between BMD and clinical factors such as globotriaosylsphingosine (lyso-Gb3) remains unclear. Therefore, the current study sought to investigate BMD in FD patients, the relationship between BMD and lyso-Gb3, and the effects of enzyme replacement therapy (ERT) on changes in BMD and lyso-Gb3. METHODS: This single-center, observational study included 15 patients who visited our facility for FD between January 2008 and June 2021. We assessed BMD and clinical characteristics in study patients, including plasma lyso-Gb3 levels, and examined the relationship between BMD and plasma lyso-Gb3 levels, and changes in BMD after starting ERT. RESULTS: Male patients' BMD had reduced, whereas female patients' BMD was preserved. Male patients had significantly higher plasma lyso-Gb3 levels than female patients. Moreover, plasma lyso-Gb3 levels were found to be significantly related to the lumbar spine and femoral BMD. These were strongly linked with plasma lyso-Gb3 levels in male patients, whereas no strong link was observed in female patients. Furthermore, BMD significantly increased only in male patients although plasma lyso-Gb3 levels significantly decreased by ERT in all patients. CONCLUSION: BMD decreased possibly due to Gb3 accumulation, and ERT could increase BMD in male FD patients.

  Aug. 2023, Molecular genetics and metabolism, 139(4) (4), 107634 - 107634, English, International magazine

  Scientific journal

  Link to Kobe Univ. Repository (Kernel)


• 慢性腎臓病+心肥大モデルラットにおけるカルシウム受容体作動薬の効果

  岡本 英久, 能瀬 勇馬, 藤井 秀毅, 岡本 隼樹, 渡邉 健太郎, 坂本 和雄, 河野 圭志, 後藤 俊介, 西 慎一

  (一社)日本腎臓学会, May 2023, 日本腎臓学会誌, 65(3) (3), 258 - 258, Japanese

• 移植後拒絶を疑う腎機能低下から腎動脈狭窄が判明した一例

  黒野 博義, 河野 圭志, 兵頭 俊紀, 岡本 隼樹, 坂本 和雄, 後藤 俊介, 兵頭 洋二, 三宅 秀明, 藤井 秀毅

  (一社)日本移植学会, Oct. 2025, 移植, 60(2) (2), 138 - 139, Japanese


• アバコパン投与後に胆管消失症候群をきたした多発血管炎肉芽腫症の一例

  浦山 知葉, 坂本 和雄, 平井 俊行, 岡本 隼樹, 後藤 公彦, 河野 圭志, 後藤 俊介, 藤井 秀毅

  (一社)日本腎臓学会, Sep. 2025, 日本腎臓学会誌, 67(6-W) (6-W), 993 - 993, Japanese


• 混合効果モデルを用いたFabry病患者におけるSGLT2阻害薬のeGFR slopeへの影響に関する検討

  岡本 隼樹, 後藤 俊介, 藤田 美佳, 藤井 秀毅

  (一社)日本腎臓学会, Jun. 2025, 日本腎臓学会誌, 67(4) (4), 571 - 571, Japanese


• アバコパン投与後に胆管消失症候群をきたした多発血管炎肉芽腫症の一例

  浦山知葉, 坂本和雄, 平井俊行, 岡本隼樹, 後藤公彦, 河野圭志, 後藤俊介, 藤井秀毅

  2025, 日本腎臓学会誌(Web), 67(6-W) (6-W)


• 移植後拒絶を疑う腎機能低下から腎動脈狭窄が判明した一例

  黒野博義, 河野圭志, 兵頭俊紀, 岡本隼樹, 坂本和雄, 後藤俊介, 兵頭洋二, 三宅秀明, 藤井秀毅

  2025, 移植(Web), 60(2) (2)


• Cardiovascular disease in long-term dialysis patients

  岡本隼樹, 藤井秀毅

  2025, 臨床透析, 41(4) (4)


• 抗ネフリン抗体による巣状分節性糸球体硬化症再発の一例

  黒野博義, 岡本隼樹, 坂本和雄, 市川裕太, 兵頭俊紀, 河野圭志, 後藤俊介, 兵頭洋二, 野津寛大, 三宅秀明, 藤井秀毅

  2025, 日本臨床腎移植学会プログラム・抄録集, 58th


• 混合効果モデルを用いたFabry病患者におけるSGLT2阻害薬のeGFR slopeへの影響に関する検討

  岡本隼樹, 後藤俊介, 藤田美佳, 藤井秀毅

  2025, 日本腎臓学会誌(Web), 67(4) (4)


• Fabry病における酵素補充療法前後の血中Lyso-Gb3の変化率に関する検討

  平井俊行, 後藤俊介, 岡本隼樹, 坂本和雄, 河野圭志, 藤井秀毅

  2024, 日本腎臓学会誌(Web), 66(4) (4)


• Fabry病におけるSGLT2阻害薬による心・腎保護効果の検討

  藤田美佳, 岡本隼樹, 平井俊行, 後藤俊介, 藤井秀毅

  2024, 日本腎臓学会誌(Web), 66(4) (4)


• カルシウム感知受容体(CaSR)作動薬による心肥大抑制とレニン-アンジオテンシン-アルドステロン系(RAAS)の変化

  岡本英久, 能瀬勇馬, 岡本隼樹, 渡邉健太郎, 坂本和雄, 河野圭志, 後藤俊介, 藤井秀毅

  2024, 日本腎臓学会誌(Web), 66(4) (4)


• ファブリー病患者における骨密度についての知見とスクリーニングへの取り組み

  能瀬勇馬, 後藤俊介, 後藤公彦, 岡本隼樹, 藤井秀毅

  2024, 日本腎臓学会誌(Web), 66(6-W) (6-W)


• 抗ネフリン抗体の関与が疑われた巣状分節性糸球体硬化症の腎移植後再発の一例

  黒野博義, 河野圭志, 市川裕太, 兵頭俊紀, 岡本隼樹, 坂本和雄, 後藤俊介, 兵頭洋二, 野津寛大, 藤井秀毅

  2024, 移植(Web), 59(2) (2)


• 慢性腎臓病+心肥大モデルラットにおけるカルシウム受容体作動薬の効果

  岡本英久, 能瀬勇馬, 藤井秀毅, 岡本隼樹, 渡邉健太郎, 坂本和雄, 河野圭志, 後藤俊介, 西慎一

  2023, 日本腎臓学会誌(Web), 65(3) (3)


• 症例による透析患者の画像診断 透析アミロイドーシスが原因と考えられた大腿骨頸部骨折の1例

  向江翔太, 河野圭志, 石井圭, 岡本隼樹, 渡邉健太郎, 藤井秀毅, 西愼一

  2022, 臨床透析, 38(2) (2)


• 透析導入期の血清リン値の厳格管理が血管石灰化に及ぼす影響

  清水真央, 藤井秀毅, 河野圭志, 岡本隼樹, 金井大輔, 渡邉健太郎, 西慎一

  2021, 日本高血圧学会総会プログラム・抄録集(CD-ROM), 43rd


• 播種性アスペルギルス症にて急速な死の転帰を辿った糖尿病性ケトアシドーシスの1例

  岡本 隼樹, 原 賢太, 小川 雅史, 渡邉 力也, 山田 克己, 西山 勝人, 安友 佳朗, 横野 浩一

  (一社)日本糖尿病学会, Jul. 2020, 糖尿病, 63(7) (7), 510 - 510, Japanese


• 播種性アスペルギルス症にて急速な死の転帰を辿った糖尿病性ケトアシドーシスの1例

  岡本隼樹, 岡本隼樹, 原賢太, 小川雅史, 渡邉力也, 山田克己, 西山勝人, 安友佳朗, 横野浩一

  2020, 糖尿病(Web), 63(7) (7)


• 右水腎症発症を契機に診断に至ったIgG4関連大動脈周囲炎の一例

  岡本隼樹, 北村謙, 岩崎慧, 清水真央

  2019, 日本腎臓学会誌, 61(6) (6)


• 血液透析患者における二次性副甲状腺機能亢進症のレニン・アルドステロン系への影響

  河野圭志, 藤井秀毅, 渡邊周平, 渡邊健太郎, 岡本隼樹, 西慎一

  2018, 日本高血圧学会総会プログラム・抄録集(CD-ROM), 41st


• 総腸骨動脈狭窄症による急激な血圧上昇と腎機能低下を認めた腎移植患者の一例

  岡本隼樹, 河野圭志, 藤井秀毅, 斎藤慶, 北村謙, 西慎一

  2018, 日本高血圧学会総会プログラム・抄録集(CD-ROM), 41st


• シナカルセト内服を契機に頻脈発作が増悪した一例

  岡本隼樹, 吉川美喜子, 細川望美, 後藤俊介, 藤井秀毅, 西愼一

  2017, 日本透析医学会雑誌, 50(Supplement 1) (Supplement 1)